Prostate Cancer Screening Articles & Analysis
6 articles found
Enzymes are biological catalysts that accelerate chemical reactions in living organisms. In recent years, enzymes have been increasingly utilized in medical diagnostics, leading to significant advancements in disease detection and management. Enzyme-based diagnostic tools have revolutionized the healthcare industry, offering numerous benefits such as increased accuracy, sensitivity, and speed. ...
Movember is an annual initiative where men from around the globe grow mustaches to raise awareness for men’s health causes, including mental health and suicide prevention, testicular cancer, and prostate cancer. Through events, fundraising, and using mustaches as a light-hearted starting point for important conversations, the movement supports men in taking charge of their health to live ...
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site ...
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
Summary OTraces, in collaboration with the Johns Hopkins Medical Center, Brady Urology Institute (JHMC), performed a blinded validation study on OTraces prostate cancer (PCa) detection products. The blinded validation project involves two phases, and the first has been completed: Phase I: Blinded third party validation of the test for men with aggressive PCa, Gleason score of 7(4+3), 8, 9, and ...